Switching from aflibercept to ranibizumab biosimilars maintains stability in nAMD treatment, offering a cost-effective ...

Explore the safety and efficacy of switching to etanercept biosimilars, backed by clinical trials and real-world evidence for ...

FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving ...

There are critical gaps in biosimilar adoption for pediatric patients, focusing on safety, regulatory challenges, and the ...

Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...

Explore the latest developments in the US biosimilar market, highlighting key approvals, challenges, and future trends ...

Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics ...

Biosimilar development costs could plummet from $100 million to $5 million, enabling smaller companies to enter the market and revolutionize access to essential medicines.

Discover the top 5 regulatory biosimilar news of 2025, highlighting FDA approvals that enhance treatment options and competition in health care. In 2025, the FDA continued to rapidly expand access to ...

Tyruko, the first natalizumab biosimilar for multiple sclerosis, promises significant savings and competition in the US market. The launch of natalizumab-sztn (Tyruko) marked a milestone for ...

Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and ...